Literature DB >> 21148492

Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit.

Catherine Moore1, Monica Galiano, Angie Lackenby, Tamer Abdelrahman, Rosemary Barnes, Meirion R Evans, Christopher Fegan, Susannah Froude, Mark Hastings, Steven Knapper, Emma Litt, Nicola Price, Roland Salmon, Mark Temple, Eleri Davies.   

Abstract

We describe the first confirmed person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus that occurred in a hematology unit in the United Kingdom. Eleven cases of (H1N1) 2009 virus infection were identified, of which, ten were related as shown by sequence analysis of the hemagglutinin and neuraminidase genes. H275Y analysis demonstrated that 8 of 10 case patients had oseltamivir-resistant virus, with 4 of 8 case patients infected by direct transmission of resistant virus. Zanamivir should be considered as first-line therapy for influenza in patients with lymphopenic hematological conditions and uptake of influenza vaccination encouraged to further reduce the number of susceptible individuals.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21148492      PMCID： PMC3086444          DOI： 10.1093/infdis/jiq007

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  13 in total

1.  Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses.

Authors:  J Ellis; M Iturriza; R Allen; A Bermingham; K Brown; J Gray; D Brown
Journal:  Euro Surveill       Date:  2009-06-04

2.  Update: influenza activity - United States, September 28, 2008--January 31, 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-02-13       Impact factor: 17.586

3.  Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe.

Authors:  A Lackenby; O Hungnes; S G Dudman; A Meijer; W J Paget; A J Hay; M C Zambon
Journal:  Euro Surveill       Date:  2008-01-31

Review 4.  2009 H1N1 influenza.

Authors:  Seth J Sullivan; Robert M Jacobson; Walter R Dowdle; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2009-12-10       Impact factor: 7.616

5.  Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.

Authors:  Jack T Nguyen; Justin D Hoopes; Minh H Le; Donald F Smee; Amy K Patick; Dennis J Faix; Patrick J Blair; Menno D de Jong; Mark N Prichard; Gregory T Went
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

6.  Update: novel influenza A (H1N1) virus infection - Mexico, March-May, 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-06-05       Impact factor: 17.586

7.  Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.

Authors:  Angie Lackenby; Jane Democratis; Marilda M Siqueira; Maria C Zambon
Journal:  Antivir Ther       Date:  2008

8.  Insomnia and depression during protective isolation in patients with hematological disorders.

Authors:  Akane Kunitomi; Hiroatsu Iida; Yoshikazu Kamiya; Mayuko Hayashi; Taro Suwa; Junya Kanda; Hiroshi Sao
Journal:  Intern Med       Date:  2010-01-01       Impact factor: 1.271

9.  Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-09-11       Impact factor: 17.586

10.  Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus.

Authors:  Jairo Gooskens; Marcel Jonges; Eric C J Claas; Adam Meijer; Peterhans J van den Broek; Aloyj M Kroes
Journal:  JAMA       Date:  2009-03-02       Impact factor: 56.272
View more
  32 in total

1.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.

Authors:  Maki Kiso; Tiago J S Lopes; Seiya Yamayoshi; Mutsumi Ito; Makoto Yamashita; Noriko Nakajima; Hideki Hasegawa; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

3.  Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity.

Authors:  Ji Wang; Peiyu Li; Yang Yu; Yuhong Fu; Hongye Jiang; Min Lu; Zhiping Sun; Shibo Jiang; Lu Lu; Mei X Wu
Journal:  Science       Date:  2020-02-21       Impact factor: 47.728

4.  Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.

Authors:  Jizhou Wang; Chunlong Ma; Jun Wang; Hyunil Jo; Belgin Canturk; Giacomo Fiorin; Lawrence H Pinto; Robert A Lamb; Michael L Klein; William F DeGrado
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

5.  Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.

Authors:  Diana D Y Wong; Ka-Tim Choy; Renee W Y Chan; Sin Fun Sia; Hsin-Ping Chiu; Peter P H Cheung; Michael C W Chan; J S Malik Peiris; Hui-Ling Yen
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

6.  Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.

Authors:  Min-Suk Song; Bindumadhav M Marathe; Gyanendra Kumar; Sook-San Wong; Adam Rubrum; Mark Zanin; Young-Ki Choi; Robert G Webster; Elena A Govorkova; Richard J Webby
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

7.  A study in scarlet-convalescent plasma for severe influenza*.

Authors:  John H Beigel; Thomas C Luke
Journal:  Crit Care Med       Date:  2012-03       Impact factor: 7.598

8.  High-resolution melting approach to efficient identification and quantification of H275Y mutant influenza H1N1/2009 virus in mixed-virus-population samples.

Authors:  Hong Kai Lee; Chun Kiat Lee; Tze Ping Loh; Julian Wei-Tze Tang; Paul Anantharajah Tambyah; Evelyn Siew-Chuan Koay
Journal:  J Clin Microbiol       Date:  2011-08-24       Impact factor: 5.948

Review 9.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

Authors:  Jennifer L McKimm-Breschkin
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

Review 10.  Influenza prevention and treatment in transplant recipients and immunocompromised hosts.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.